When insiders buy shares on the open market, their companies are usually undervalued. Corporate insiders often have the inside track on their companies' prospects. Insiders probably wouldn't risk investing too much of their own money into their own companies unless they thought the stock might rise.
I screened for companies where at least one insider made an insider buy on June 29. Here are three healthcare stocks that I found:
1. Urologix (OTC:ULGX) develops, manufactures and markets minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix' Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort while providing safe, effective, lasting relief of the symptoms and obstruction due to BPH. Urologix' Cooled ThermoTherapy products include the CoolWave and Targis Control Units and the CTC Advance and Targis catheter families.
Urologix has an Exclusive License Agreement for the Prostiva RF Therapy product line. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, which reduces constriction of the urethra, thereby relieving BPH voiding symptoms. Over 100,000 procedures have been performed in the last 10 years and the therapy is supported by multiple peer reviewed published articles demonstrating safety and efficacy through five years of follow-up.
Click to enlarge
Insider buys
- Mitchell Dann purchased 100,000 shares directly and 100,000 shares by a trust on June 29 and currently holds 568,375 shares of the company.
- Sidney Emery purchased 20,000 shares on June 29 and currently controls 133,307 shares of the company.
- Stryker Warren (Chief Executive Officer) purchased 200,000 shares on June 29 and currently holds 457,280 shares of the company
2. Anthera Pharmaceuticals (OTC:ANTH) is a biopharmaceutical company focused on developing and commercializing products to
